$0.50
1.00% yesterday
Nasdaq, Jul 28, 10:00 pm CET
ISIN
US75120L1008
Symbol
RLYB

Rallybio Corp Stock price

$0.50
+0.17 49.02% 1M
-0.39 43.33% 6M
-0.46 47.53% YTD
-0.82 61.84% 1Y
-9.28 94.85% 3Y
-13.60 96.43% 5Y
-13.60 96.43% 10Y
-13.60 96.43% 20Y
Nasdaq, Closing price Mon, Jul 28 2025
+0.01 1.00%
ISIN
US75120L1008
Symbol
RLYB
Industry

Key metrics

Basic
Market capitalization
$20.8m
Enterprise Value
$-33.8m
Net debt
positive
Cash
$54.5m
Shares outstanding
41.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
24.4 | 98.8
EV/Sales
negative | negative
EV/FCF
0.8
P/B
0.4
Financial Health
Equity Ratio
90.5%
Return on Equity
-93.7%
ROCE
-93.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$850.0k | $210.1k
EBITDA
$-50.3m | $-68.3m
EBIT
$-50.4m | $-41.9m
Net Income
$-48.2m | $-35.9m
Free Cash Flow
$-44.0m
Growth (TTM | estimate)
Revenue
- | -67.2%
EBITDA
37.3% | -13.2%
EBIT
37.3% | 30.7%
Net Income
36.8% | 37.9%
Free Cash Flow
22.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-5,926.3% | -32,524.3%
EBIT
-5,940.9%
Net
-5,682.2% | -17,068.2%
Free Cash Flow
-5,192.2%
More
EPS
$-1.1
FCF per Share
$-1.1
Short interest
5.9%
Employees
25
Rev per Employee
$30.0k
Show more

Is Rallybio Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Rallybio Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Rallybio Corp forecast:

6x Buy
55%
5x Hold
45%

Analyst Opinions

11 Analysts have issued a Rallybio Corp forecast:

Buy
55%
Hold
45%

Financial data from Rallybio Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.85 0.85
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
32% 32%
1,992%
- Research and Development Expense 34 34
38% 38%
4,035%
-50 -50
37% 37%
-5,913%
- Depreciation and Amortization 0.12 0.12
20% 20%
14%
EBIT (Operating Income) EBIT -50 -50
37% 37%
-5,927%
Net Profit -48 -48
37% 37%
-5,669%

In millions USD.

Don't miss a Thing! We will send you all news about Rallybio Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rallybio Corp Stock News

Neutral
Business Wire
21 days ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hy...
Neutral
Business Wire
about 2 months ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small v...
Neutral
Business Wire
3 months ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments. “We are focused on advancing RLYB116 int...
More Rallybio Corp News

Company Profile

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focuses in the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Head office United States
CEO Stephen Uden
Employees 25
Founded 2018
Website rallybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today